Search

Your search keyword '"Iftikhar, P"' showing total 66 results
Start Over Author "Iftikhar, P" Journal blood
66 results on '"Iftikhar, P"'

3. ELN 2022 Favorable Genetic Risk Acute Myeloid Leukemia Treated with Venetoclax Plus Hypomethylating Agent: Predictors of Response and Survival

Author

McCullough, Kristen, Karrar, Omer, Iftikhar, Moazah, Abdelmagid, Maymona, Al-Kali, Aref, Alkhateeb, Hassan, Begna, Kebede, Mangaonkar, Abhishek A, Saliba, Antoine, Hefazi, Mehrdad, Litzow, Mark R., Hogan, William J., Shah, Mithun V, Patnaik, Mrinal M., Pardanani, Animesh D., Tefferi, Ayalew, and Gangat, Naseema

Abstract

Background:

Published
2023
Full Text
View/download PDF

5. Survival and Prognosis Among 301 Patients with Newly-Diagnosed Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy

Author

Karrar, Omer, Iftikhar, Moazah, McCullough, Kristen, Johnson, Isla, Abdelmagid, Maymona, Al-Kali, Aref, Alkhateeb, Hassan, Begna, Kebede, Mangaonkar, Abhishek A, Saliba, Antoine, Hefazi, Mehrdad, Litzow, Mark R., Hogan, William J., Shah, Mithun V, Patnaik, Mrinal M., Pardanani, Animesh D., Badar, Talha, Murthy, Hemant S., Foran, James M., Palmer, Jeanne, Sproat, Lisa, Khera, Nandita, Arana Yi, Cecilia Y., Tefferi, Ayalew, and Gangat, Naseema

Abstract

Background:

Published
2023
Full Text
View/download PDF

6. A Systematic Review of Transfusion Transmissible Infections Among Blood Donors and Associated Safety Challenges in Pakistan

Author

Ehsan, Hamid, Wahab, Ahsan, Shafqat, Muhammad Ammar, Sana, Muhammad Khawar, Khalid, Farhan, Tayyeb, Muhammad, Muneeb, Ahmad, Khan, Ali Younas, Ehsan, Sajid, Ehsan, Amrat, Iftikhar, Raheel, and Anwer, Faiz

Abstract

Anwer: Incyte, Seattle Genetics, Acetylon Pharmaceuticals, AbbVie Pharma, Astellas Pharma, Celegene, Millennium Pharmaceuticals.:Honoraria, Research Funding, Speakers Bureau.

Published
2020
Full Text
View/download PDF

7. Prevalence of Transfusion Transmissible Infections in Beta-Thalassemia Major Patients of Pakistan: A Systematic Review

Author

Ehsan, Hamid, Wahab, Ahsan, Shafqat, Muhammad Ammar, Faisal, Muhammad Salman, Muneeb, Ahmad, Ali, Sundas, Sana, Muhammad Khawar, Khalid, Farhan, Ansar, Iqraa, Jaan, Ali, Iftikhar, Raheel, and Anwer, Faiz

Abstract

Anwer: Incyte, Seattle Genetics, Acetylon Pharmaceuticals, AbbVie Pharma, Astellas Pharma, Celegene, Millennium Pharmaceuticals.:Honoraria, Research Funding, Speakers Bureau.

Published
2020
Full Text
View/download PDF

11. Current Use of Androgens in Bone Marrow Failure Disorders: A Report from the Severe Aplastic Anemia Working Party (SAAWP) of the European Society of Blood and Marrow Transplantation (EBMT)

Author

Pagliuca, Simona, Kulasekararaj, Austin, Eikema, Dirk-Jan, Piepenbroek, Brian, Iftikhar, Raheel, Satti, Tariq Mahmood, Griffin, Morag, Laurino, Marica, Kupesiz, O. Alphan, Bertrand, Yives, Fattizzo, Bruno, Yakoub-Agha, Ibrahim, Aljurf, Mahmoud, Corti, Paola, Massaccesi, Erika, Lioure, Bruno, Calabuig, Marisa, Klammer, Matthias, Unal, Emel, Wu, Depei, Chevallier, Patrice, Forcade, Edouard, Snowden, John A., Ozdogu, Hakan, Risitano, Antonio, and Peffault de Latour, Régis

Published
2022
Full Text
View/download PDF

16. Current Use of Androgens in Bone Marrow Failure Disorders: A Report from the Severe Aplastic Anemia Working Party (SAAWP) of the European Society of Blood and Marrow Transplantation (EBMT)

Author

Pagliuca, Simona, Kulasekararaj, Austin, Eikema, Dirk-Jan, Piepenbroek, Brian, Iftikhar, Raheel, Satti, Tariq Mahmood, Griffin, Morag, Laurino, Marica, Kupesiz, O. Alphan, Bertrand, Yives, Fattizzo, Bruno, Yakoub-Agha, Ibrahim, Aljurf, Mahmoud, Corti, Paola, Massaccesi, Erika, Lioure, Bruno, Calabuig, Marisa, Klammer, Matthias, Unal, Emel, Wu, Depei, Chevallier, Patrice, Forcade, Edouard, Snowden, John A., Ozdogu, Hakan, Risitano, Antonio, and Peffault de Latour, Régis

Published
2022
Full Text
View/download PDF

20. CD-19 Specific CAR-T Cell Therapy in Relapsed/Refractory ALL in Pediatrics and Young Adults; Safety and Efficacy Outcomes: A Systematic Review and Meta-Analysis

Author

Aamir, Sobia, Ali, Muhammad Ashar, Khan, Sana Irfan, Dar, Abdul Jabbar, Khalid, Farhan, Anwar, Muhammad Yasir, Tayyeb, Muhammad, Khan, Anam, Khan, Atif Irfan, Batool, Syeda Sabeeka, Akbar, Arshia, Iftikhar, Seemal, and Anwer, Faiz

Abstract

Anwer: Incyte, Seattle Genetics, Acetylon Pharmaceuticals, AbbVie Pharma, Astellas Pharma, Celegene, Millennium Pharmaceuticals.:Honoraria, Research Funding, Speakers Bureau.

Published
2020
Full Text
View/download PDF

22. Cytomegalovirus Reactivation in Hematopoietic Stem Cell Transplant Recipients in High Endemic Population

Author

Farhan, Muhammad, Chaudhry, Qamar Un Nisa, Mahmood, Syed Kamran, Ghafoor, Tariq, Iftikhar, Raheel, Shahbaz, Nighat, Khan, Mehreen Ali, Khattak, Tariq, Shamshad, Ghassan, Rehman, Jahanzeb, and Ahmed, Parvez

Abstract

Background:Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality after hematopoietic stem cell transplantation (HSCT). It causes end-organ disease, multi-organ dysfunction syndrome, graft failure, increased susceptibility to infections and GVHD. According to the published western data greatest risk of CMV infection is the seropositivity of the recipient, however, in a high endemic population where seropositivity is up to 100%, risk factors for CMV reactivation are different and are analyzed in this study.

Published
2020
Full Text
View/download PDF

26. Efficacy and Safety Profile of Ixazomib Based Regimens in Relapsed/Refractory Multiple Myeloma: A Meta-Analysis of Clinical Trials

Author

Iftikhar, Ahmad, Ali, Muhammad Ashar, Javaid, Anum, Abu Zar, Muhammad, Sohail, Atif, Razzaq, Faryal, Usman, Rana M, Anwar, Muhammad Yasir, Hassan, Hamza, and Anwer, Faiz

Abstract

Anwer: Incyte, Seattle Genetics, Acetylon Pharmaceuticals, AbbVie Pharma, Astellas Pharma, Celegene, Millennium Pharmaceuticals.: Honoraria, Research Funding, Speakers Bureau.

Published
2020
Full Text
View/download PDF

30. Patterns of Relapse and Treatment for Relapsed/Refractory AL Amyloidosis: A Systematic Review

Author

Mushtaq, Adeela, Hassan, Hamza, Khanam, Razwana, Iftikhar, Ahmad, Lakhani, Midhat, Yousaf, Muhammad Abdullah, Ahmad, Muhaddis Ejaz, Yusufi, Maaz Ahmed, Iftikhar, Seemal, Zafar, Aneeqa A, Riaz, Irbaz, Sidiqi, M Hasib, and Anwer, Faiz

Abstract

Anwer: Seattle Genetics: Membership on an entity's Board of Directors or advisory committees; In-Cyte: Speakers Bureau.

Published
2019
Full Text
View/download PDF

33. Specificity of CD8-Targeted Fusosomes in Human PBMCs Using Single Cell RNA and T Cell Receptor Sequencing

Author

Iftikhar, Hina, Balanis, Nikolas, Fonseka, Chamith, Bandoro, Christopher, Cruite, Patricia, Davis, Samantha, Amatya, Shirisha, Frye, Zach, Pepper, Lauren, Laska, Michael, Fry, Terry J., Shah, Jagesh V, Paliwal, Saurabh, and Chaivorapol, Christina

Abstract

Introduction:The ability to deliver genes to specific cell types in vivowould have a profound therapeutic impact for a diverse set of diseases. For example, targeting T cells for in vivodelivery of a chimeric antigen receptor (CAR) to treat B cell malignancies would improve access to CAR T therapies by overcoming the limitations of ex vivomanufacturing such as high costs, wait times and manufacturing failures. We have developed a novel paramyxovirus-based integrating vector (fusosomes) that specifically targets cell surface receptors for targeted gene delivery. Fusosomes, engineered to target CD8α, a cell surface protein expressed on CD8+ T cells, can bind and specifically deliver a genetic payload through membrane fusion. To evaluate the specificity of fusosome-mediated delivery to cells expressing CD8α in vitro, single cell RNA sequencing (scRNA-seq) and T cell receptor sequencing (scTCR-seq) were performed on human PBMCs treated with CD8α-targeted fusosomes with a GFP payload. scRNA-seq is a tool that can be used to detect the transgene delivered by our fusosomes in specific cell populations by measuring mRNA expression of the receptor targeted by the fusosome (e.g., CD8α) and the genetic payload delivered by the fusosome in the same cell. Transcriptome information to understand potential pathway changes induced by delivery of the transgene is also captured.

Published
2021
Full Text
View/download PDF

34. Diagnosis and Management of Diffuse Large B Cell Lymphoma in Resource Constraint Settings: Society of Medical Oncology Pakistan, Pakistan Society of Haematology and Pakistan Society of Clinical Oncology Joint Clinical Practice Guideline

Author

Iftikhar, Raheel, Ayaz Mir, Muhammad, Moosajee, Munira, Rasheed, Kamran, Imam Bukhari, Syed Waqas, Nadeem Abbasi, Ahmed, Shamsi, Tahir Sultan, Khan, Maryam, Ahmed, Parvez, ud Din, Hafeez, Chaudhry, Qamar un Nisa, Ahmad, Imran N, Ali, Natasha, Umair, Muhammad, Bangash, Mussavir, Ahmad, Usman, Sattar, Wasim, Zargham, Anum, Shafi, Azhar, Shamshad, Ghassan U., Rizvi, Qurratulain, Usman Shaikh, Mohammad, Muhammad Irfan, Syed, Zaidi, Uzma, Naqi, Naeem, Mahmood, Humera, Hussain, Asghar, Ijaz Masood, Ahmed, Siddiqui, Neelam, Masood, Misbah, Faheem, Mohammad, Adil, Salman Naseem, and Aziz, Zeba

Abstract

Purpose: To provide evidence-based recommendations for health care professionals on diagnosis and management of diffuse large B cell lymphoma (DLBCL) in resource constraint settings with variable and often limited access to standard of care and advanced diagnostic and therapeutic facilities.

Published
2021
Full Text
View/download PDF

35. Specificity of CD8-Targeted Fusosomes in Human PBMCs Using Single Cell RNA and T Cell Receptor Sequencing

Author

Iftikhar, Hina, Balanis, Nikolas, Fonseka, Chamith, Bandoro, Christopher, Cruite, Patricia, Davis, Samantha, Amatya, Shirisha, Frye, Zach, Pepper, Lauren, Laska, Michael, Fry, Terry J., Shah, Jagesh V, Paliwal, Saurabh, and Chaivorapol, Christina

Abstract

Iftikhar: Sana Biotechnology: Current Employment. Balanis: Sana Biotechnology: Ended employment in the past 24 months. Fonseka: Sana Biotechnology: Current Employment. Bandoro: Sana Biotechnology: Ended employment in the past 24 months. Cruite: Sana Biotechnology: Current Employment. Davis: Sana Biotechnology: Current Employment. Amatya: Sana Biotechnology: Current Employment. Frye: Sana Biotechnology: Current Employment. Pepper: Sana Biotechnology: Current Employment. Laska: Sana Biotechnology: Current Employment. Fry: Sana Biotechnology: Current Employment, Current equity holder in publicly-traded company. Shah: Sana Biotechnology: Current Employment. Paliwal: Sana Biotechnology: Current Employment. Chaivorapol: Sana Biotechnology: Current Employment.

Published
2021
Full Text
View/download PDF

36. Successful Outpatient Administration of Blinatumomab Infusion in Pediatric Patients with Acute Lymphoblastic Leukemia

Author

Bojilova-Dor, Lora, Pinkney, Kerice, Cauff, Brian, Kramer, Deborah, Schaefer, Anne M, Ballestas, Carmen, Diaz, Melissa H, Stevens, Joan Spiro, Grunwald, Haley, Siryk, Ashley, O'Neill, Becky, Pereira, Maricel, Khalif, Caroline, Moretti, Caroline, Shenderov, Faina, and Hanif, Iftikhar

Abstract

No relevant conflicts of interest to declare.

Published
2021
Full Text
View/download PDF

37. Outcomes of Haploidentical Stem Cell Transplantation in Patients with Fanconi Anemia; A Systematic Review

Author

Shah, Zunairah, Khan, Israr, Baloch, Ali Shahbaz, Awal, Talha, Aamir, Sobia, Anjum, Ali, Usman, Norina, Haider, Mobeen Zaka, Anwer, Faiz, and Iftikhar, Raheel

Abstract

Anwer: Allogene Therapeutics: Research Funding; GlaxoSmithKline: Research Funding; Janssen pharmaceutical: Honoraria, Research Funding; BMS / Celgene: Honoraria, Research Funding.

Published
2021
Full Text
View/download PDF

38. Diagnosis and Management of Diffuse Large B Cell Lymphoma in Resource Constraint Settings: Society of Medical Oncology Pakistan, Pakistan Society of Haematology and Pakistan Society of Clinical Oncology Joint Clinical Practice Guideline

Author

Iftikhar, Raheel, Ayaz Mir, Muhammad, Moosajee, Munira, Rasheed, Kamran, Imam Bukhari, Syed Waqas, Nadeem Abbasi, Ahmed, Shamsi, Tahir Sultan, Khan, Maryam, Ahmed, Parvez, ud Din, Hafeez, Chaudhry, Qamar un Nisa, Ahmad, Imran N, Ali, Natasha, Umair, Muhammad, Bangash, Mussavir, Ahmad, Usman, Sattar, Wasim, Zargham, Anum, Shafi, Azhar, Shamshad, Ghassan U., Rizvi, Qurratulain, Usman Shaikh, Mohammad, Muhammad Irfan, Syed, Zaidi, Uzma, Naqi, Naeem, Mahmood, Humera, Hussain, Asghar, Ijaz Masood, Ahmed, Siddiqui, Neelam, Masood, Misbah, Faheem, Mohammad, Adil, Salman Naseem, and Aziz, Zeba

Abstract

No relevant conflicts of interest to declare.

Published
2021
Full Text
View/download PDF

39. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes [see comments]

Author

Raza, A, Gezer, S, Mundle, S, Gao, XZ, Alvi, S, Borok, R, Rifkin, S, Iftikhar, A, Shetty, V, and Parcharidou, A

Abstract

Cell-cycle kinetics were measured in situ after infusions of iododeoxyuridine and/or bormodeoxyuridine in 50 patients with myelodysplastic syndromes (MDS) and the median labeling index in bone marrow (BM) biopsy samples was 28.6%. Unfortunately, 26 of 50 patients showed that > or = 75% of hematopoietic cells of all three lineages were undergoing programmed cell death (PCD) in their biopsy samples as shown by the in situ end labeling (ISEL) technique. Ten patients had 1/3 and eight had 2/3 ISEL+ cells. Stromal cells were frequently ISEL+ and often S-phase cells were also found to be simultaneously ISEL+. Nucleosomal DNA fragments as a ladder in agarose gel were present in BM aspirates of four patients who showed high ISEL and were absent in two who had no ISEL staining in biopsy samples, but only when DNA was extracted after a 4-hour in vitro incubation in complete medium. Therefore, laddering data confirmed the ISEL findings that the majority of hematopoietic cells in MDS are in early stages of PCD. We conclude that extensive intramedullary cell death may explain the paradox of pancytopenia despite hypercellular marrows in MDS patients. Investigating approaches that protect against PCD in some MDS subsets would be of interest.

Published
1995
Full Text
View/download PDF

40. Apoptosis in Bone Marrow Biopsy Samples Involving Stromal and Hematopoietic Cells in 50 Patients With Myelodysplastic Syndromes

Author

Raza, Azra, Gezer, Sefer, Mundle, Suneel, Gao, Xue-Zhi, Alvi, Sairah, Borok, Raphael, Rifkin, Shelby, Iftikhar, Amna, Shetty, Vilasini, Parcharidou, Agapi, Loew, Jerome, Marcus, Bridget, Khan, Zaineb, Chaney, Colette, Showel, John, Gregory, Stephanie, and Preisler, Harvey

Abstract

Cell-cycle kinetics were measured in situ after infusions of iododeoxyuridine and/or bromodeoxyuridine in 50 patients with myelodysplastic syndromes (MDS) and the median labeling index in bone marrow (BM) biopsy samples was 28.6%. Unfortunately, 26 of 50 patients showed that ≥75% of hematopoietic cells of all three lineages were undergoing programmed cell death (PCD) in their biopsy samples as shown by the in situ end labeling (ISEL) technique. Ten patients had 1/3 and eight had 2/3 ISEL+cells. Stromal cells were frequently ISEL+and often S-phase cells were also found to be simultaneously ISEL+. Nucleosomal DNA fragments as a ladder in agarose gel were present in BM aspirates of four patients who showed high ISEL and were absent in two who had no ISEL staining in biopsy samples, but only when DNA was extracted after a 4-hour in vitro incubation in complete medium. Therefore, laddering data confirmed the ISEL findings that the majority of hematopoietic cells in MDS are in early stages of PCD. We conclude that extensive intramedullary cell death may explain the paradox of pancytopenia despite hypercellular marrows in MDS patients. Investigating approaches that protect against PCD in some MDS subsets would be of interest.

Published
1995
Full Text
View/download PDF

42. Ixazomib Based Regimens in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis of Clinical Trials

Author

Javaid, Anum, Razzaq, Faryal, Ali, Muhammad Ashar, Abu Zar, Muhammad, Sohail, Atif, Iftikhar, Ahmad, Usman, Rana, Anwar, Muhammad Yasir, Hassan, Hamza, and Anwer, Faiz

Abstract

Anwer: Incyte, Seattle Genetics, Acetylon Pharmaceuticals, AbbVie Pharma, Astellas Pharma, Celegene, Millennium Pharmaceuticals.: Honoraria, Research Funding, Speakers Bureau.

Published
2020
Full Text
View/download PDF

44. Efficacy and Safety Profile of Bortezomib Based Regimens for Treatment of Newly Diagnosed Amyloidosis: A Systematic Review of Literature

Author

Yousaf, Muhammad Abdullah, Ahmad, Muhaddis Ejaz, Yusufi, Maaz Ahmed, Hassan, Hamza, Mushtaq, Adeela, Iftikhar, Ahmad, Malik, Mustafa Nadeem, Rafae, Abdul, Shah, Zunairah, Ibrahim, Ahmed, Basheer, Adnan, and Anwer, Faiz

Abstract

Introduction: For more than a decade, bortezomib (V) has become an integral part of initial treatment of AL amyloidosis It is cytotoxic to plasma cells. We report published literature on efficacy and safety of bortezomib based regimens in patients (pts) with newly diagnosed amyloidosis (ND-AL).

Published
2019
Full Text
View/download PDF

45. Efficacy and Safety Profile of Bortezomib Based Regimens for Treatment of Newly Diagnosed Amyloidosis: A Systematic Review of Literature

Author

Yousaf, Muhammad Abdullah, Ahmad, Muhaddis Ejaz, Yusufi, Maaz Ahmed, Hassan, Hamza, Mushtaq, Adeela, Iftikhar, Ahmad, Malik, Mustafa Nadeem, Rafae, Abdul, Shah, Zunairah, Ibrahim, Ahmed, Basheer, Adnan, and Anwer, Faiz

Abstract

Anwer: In-Cyte: Speakers Bureau; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees.

Published
2019
Full Text
View/download PDF

48. Pomalidomide Based Regimens for Treatment of Relapsed Multiple Myeloma: A Systematic Review and Meta-Analysis of Clinical Trials

Author

Mushtaq, Adeela, Iftikhar, Ahmad, Lakhani, Midhat, Sagar, Fnu, Kamal, Ahmad, Zahid, Umar, Hassan, Hamza, Ali, Zeeshan, Razzaq, Faryal, Malik, Saad Ullah, Hassan, Syeda Fatima, Abu Zar, Muhammad, Bilal Chaudhary, Mohammad, Safdar, Ahmad, Bakr, Mohamed Mokhtar, and Anwer, Faiz

Abstract

No relevant conflicts of interest to declare.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results